Preformulation and Development of a Once-Daily Sustained-Release Tenofovir Vaginal Tablet Tablet Containing A Single Excipient

Christopher McConville, David R Friend, Meredith R. Clark, Karl Malcolm

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tenofovir is a nucleoside reverse-transcriptase inhibitor that is currently being investigated as a potential HIV microbicide candidate, with a recent phase IIb study of a 1% (w/w) tenofovir gel reducing HIV acquisition by 39% in sexually active women. However, not only does a HIV microbicidal product need to be safe and effective, it also needs to be cheap and easy to manufacture. In this study, we report the development of a tenofovir-loaded tablet, manufactured using a single sustained-release polymer, which has an acceptable hardness, friability and tenofovir release rate. Furthermore, by varying both the type and molecular weight of the sustained-release polymer, as well as the particle size of both tenofovir and the sustained-release polymer, we can vary the release rate of tenofovir from the tablets.
Original languageEnglish
Pages (from-to)1859-1868
JournalJournal of Pharmaceutical Sciences
Volume102
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint Dive into the research topics of 'Preformulation and Development of a Once-Daily Sustained-Release Tenofovir Vaginal Tablet Tablet Containing A Single Excipient'. Together they form a unique fingerprint.

  • Cite this